Coming from you—the iHub savant of HCV—I consider that a credit to the model!
Do you have a current number for warehoused HCV patients awaiting treatment?
A prerequisite would be an operational definition of warehoused, and I suspect we could have a long thread on that.
Your $30-50K U.S. price range for ABBV combo treatment strikes me as low.
Yes, I was aiming to be conservative. (I didn’t actually mention a $50K figure, but my $30K average for the US and EU combined would clearly require something close to $50K in the US.)
I've heard analysts kicking around the $80-100k figure for GILD's combo which in turn sounds too high (perhaps disregarding competition).
Agreed. Those are the same analysts who naïvely think GILD has the all-oral HCV market locked up.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.